GU Cancers Symposium 2014 - Biomarker analysis from a phase III trial (GOLD) of dovitinib vs sorafenibin patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy - Poster

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Bernard J. Escudier, Camillo Porta, Matthew Squires, Cezary Szczylik, Christian K. Kollmannsberger, Bohuslav Melichar, Sun Young Rha, Emilio Esteban, Georg A. Bjarnason, Nicholas J. Vogelzang, Cora N. Sternberg, Michael Shi, Mathab Marker, and Robert John Motzer at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 Poster Escudier thumb

Institut Gustave Roussy, Villejuif, France; IRCCS San Matteo University Hospital Foundation, Pavia, Italy; Novartis Pharma AG, Basel, Switzerland; Military Institute of Health Services in Warsaw, Warsaw, Poland; BCCA Vancouver Cancer Centre, Vancouver, BC, Canada; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Yonsei University College of Medicine, Seoul, South Korea; Hospital Universitario Central de Asturias, Oviedo, Spain; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; San Camillo and Forlanini Hospital, Rome, Italy; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Memorial Sloan-Kettering Cancer Center, New York, NY

 

 

email news signup